The eye is an organ of brain
The eye is an organ of the brain, which is easily accessible and shares similar vasculature, anatomy and physiology to the brain.
Therefore, the molecular changes in the retina can be used as a biomarker of neurological diseases such as Alzheimer’s, if tested appropriately.
Changes in the retina can be used as a biomarker of many neurodegenerative diseases
Understanding the metabolic changes in the retina can be used as a biomarker for the detection or progression of many neurodegenerative diseases such as Alzheimer’s disease.
How accurately earlier retinal changes can be used as biomarkers for predicting different neurological diseases?
This is very complex and hard to know because different diseases might have mixed effects on the retina.
For a doctor, skilled as he may be, who looks into the eye, it will be difficult to differentiate specific diseases associated with changes in the retina.
Many AIs for health try to imitate that decision-making process of experts in their field. But when we use human knowledge to teach a machine, AI will always be limited by a human’s capabilities and knowledge gaps.
We are different.
RetiSpec’s Artificial Intelligence uses the RetiSpec hyperspectral imaging technology to detect signs of Alzheimer’s disease that are yet unknown and will later become the very first indicators in an early and accurate diagnostic process.
We capture retinal images with much broader range of the light spectrum than what is visible. The retina shares developmental and biological similarities to the brain, and imaging the retina is non-invasive.
RetiSpec gathers this data using it’s proprietary hyperspectral retinal imaging technology. These unique retinal images provides the basis for our AI.
RetiSpec’s AI uses this knowledge to unlock biological insights that no human eye can see – and no human knowledge can limit.
Hyperspectral imaging captures and processes data using a much broader range of the light spectrum than what is visible. It can be harnessed to assess the molecular, chemical, or physical information such as material quality or hidden element composition-
more than we can see with our eyes.
What makes our
Early Detection of Amyloidopathy in Alzheimer's Mice by Hyperspectral Endoscopy
Swati S. More; James M. Beach; Robert Vince
Investigative Ophthalmology & Visual Science June 2016, Vol.57, 3231-3238. doi:https://doi.org/10.1167/iovs.15-17406
Hyperspectral Imaging Signatures Detect Amyloidopathy in Alzheimer’s Mouse Retina Well before Onset of Cognitive Decline; ACS Chem.
Swati S. More and Robert Vince
ACS Chem. Neurosci. 2015, 6, 2, 306-315 https://doi.org/10.1021/cn500242z
In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease
Swati S More, James M Beach, Collin McClelland, Ali Mokhtarzadeh, Robert Vince
ACS Chem Neurosci. 2019 Nov 20;10(11):4492-4501. doi: 10.1021/acschemneuro.9b00331. Epub 2019 Oct 24.
Existing tests used to detect the hallmark pathologies of Alzheimer’s disease are prohibitively invasive and costly. RetiSpec offers a non-invasive affordable optical technology that works with existing Optometry equipment and can be completed as part of a routine eye exam.